Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2516568 | 0.85 | — | — | |
| SCHEMBL20640397 | 0.81 | — | — | |
| SCHEMBL1382368 | 0.81 | POLB (0.32) | — | |
| SCHEMBL7989979 | 0.80 | NEK2 (0.36) | NEK2CRBN | |
| SCHEMBL22422290 | 0.79 | POLB (0.35) | — | |
| SCHEMBL105607 | 0.79 | POLB (0.35) | — | |
| Hydrochloric Acid SCHEMBL5611779 | 0.78 | NEK2 (0.35) | NEK2 | |
| SCHEMBL20510103 | 0.78 | — | — | |
| SCHEMBL19094306 | 0.77 | HSD11B1 (0.30) | CRBN | |
| Hydrochloric Acid SCHEMBL19126647 | 0.77 | POLB (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131418-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARAMCEUTICALS, INC. (US) | 2009-05-21 | — | — | US | claimed |
| US-20070161621-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS (US) | 2007-07-12 | — | — | US | claimed |
| US-7217719-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. (US) | 2007-05-15 | — | — | US | claimed |
| US-20060205710-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-09-14 | — | — | US | claimed |
| US-20060199794-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | claimed |
| US-20050256108-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2005-11-17 | — | — | US | claimed |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2003-09-04 | — | — | US | claimed |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-20250092091-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE LIGANDS | Humanwell Pharmaceutical US | 2025-03-20 | — | — | US | disclosed |
| US-12215173-B2 | Kappa opioid receptor peptide amide ligands | HUMANWELL PHARMACEUTICAL US, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2025-01-30 | — | — | US | disclosed |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | CAMP4 THERAPEUTICS CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-6465478-B1 | 1,3,8-Triuazaspiro(4,5)decanone compounds as ORL1-receptor agonists | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| US-6277991-B1 | FOR TREATMENT OF MIGRAINE, NON-INSULIN DEPENDENT DIABETES MELLITUS, SEPSIS, INFLAMMATION, INCONTINENCE, VASOMOTOR DISTURBANCES SUCH AS HOT FLUSHES OR HOT FLASHES | NOVO NORDISK A/S (DK) | 2001-08-21 | — | — | US | disclosed |
| EP-1080091-A1 | NOVEL 1,3,8-TRIAZASPIRO[4.5]DECANONES WITH HIGH AFFINITY FOR OPIOID RECEPTOR SUBTYPES | Novo Nordisk A/S (DK) | 2001-03-07 | — | — | EP | disclosed |
| JP-2000128879-A | 1,3,8-TRIAZASPIRO[4.5]DECANONE COMPOUND AS ORL1-RECEPTOR AGONIST | PFIZER PHARMACEUTICALS INC | 2000-05-09 | — | — | JP | disclosed |
| EP-0997464-A1 | 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists | PFIZER INC. (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999059997-A1 | NOVEL 1,3,8-TRIAZASPIRO[4.5]DECANONES WITH HIGH AFFINITY FOR OPIOID RECEPTOR SUBTYPES | NOVO NORDISK A/S (DK) | 1999-11-25 | — | — | WO | disclosed |
| WO-1997000872-A1 | 1,3,8-TRIAZA- AND 3,8-DIAZA-1-OXASPIRO(4,5)DECANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1997-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256108-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | NEK2 1009/4885CRBN 4179/4885 |
| US-20060205710-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | NEK2 1009/4885CRBN 4179/4885 |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | NEK2 762/4885CRBN 4270/4885 |
| US-20090131418-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | MAOA, MAOB, HTR5A | NEK2 1009/4885CRBN 4179/4885 |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | NEK2 1009/4885CRBN 4179/4885 |
| US-20250092091-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE LIGANDS | OPRK1, OPRL1, OPRD1 | NEK2 4186/4885CRBN 4117/4885 |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | NEK2 269/4885CRBN 810/4885 |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | RPLP2, RPS2, RPLP1 | NEK2 555/4885CRBN 458/4885 |
| US-12215173-B2 | Kappa opioid receptor peptide amide ligands | OPRK1, OPRL1, OPRD1 | NEK2 4186/4885CRBN 4117/4885 |
| US-20070161621-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | MAOA, MAOB, HTR5A | NEK2 1009/4885CRBN 4179/4885 |
| US-20060199794-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | NEK2 1009/4885CRBN 4179/4885 |
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | RPLP2, RPS2, RPLP1 | NEK2 555/4885CRBN 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.